Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Nature
|
March 27, 2025
Some assembly required
Russell Nichols
Nature
|
July 31, 2020
Trash can rap
Russell Nichols
Nature
|
October 19, 2022
The family tree
Russell Nichols
Journal of the American Association for Laboratory Animal Science : JAALAS
|
July 8, 2022
Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy
Goldia Chan, Catherine Si, M Russell Nichols, et al.
The Lancet. Neurology
|
July 15, 2019
Approvals and indications of CGRP antibodies
Russell Nichols, Holland C Detke, Hans-Peter Hundemer, et al.
Journal of Geriatric Psychiatry and Neurology
|
June 6, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances
Ilya Lipkovich, Jonna Ahl, Russell Nichols, et al.
Headache
|
June 9, 2020
A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
Louise Lombard, Wenyu Ye, Russell Nichols, et al.
The Journal of Headache and Pain
|
March 3, 2019
Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Russell Nichols, Vladimir Skljarevski, Grazia Dell'Agnello, et al.
Headache
|
November 22, 2018
Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
Russell Nichols, Erin Doty, Sara Sacco, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
September 15, 2020
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
Janet Ford, Cristina Tassorelli, Elizabeth Leroux, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Nature
|
March 27, 2025
Some assembly required
Russell Nichols
Nature
|
July 31, 2020
Trash can rap
Russell Nichols
Nature
|
October 19, 2022
The family tree
Russell Nichols
Journal of the American Association for Laboratory Animal Science : JAALAS
|
July 8, 2022
Assessment of the Safety and Efficacy of Pre-emptive Use of Extended-release Buprenorphine for Mouse Laparotomy
Goldia Chan, Catherine Si, M Russell Nichols, et al.
The Lancet. Neurology
|
July 15, 2019
Approvals and indications of CGRP antibodies
Russell Nichols, Holland C Detke, Hans-Peter Hundemer, et al.
Journal of Geriatric Psychiatry and Neurology
|
June 6, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances
Ilya Lipkovich, Jonna Ahl, Russell Nichols, et al.
Headache
|
June 9, 2020
A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment
Louise Lombard, Wenyu Ye, Russell Nichols, et al.
The Journal of Headache and Pain
|
March 3, 2019
Letter to the editor regarding European Headache Federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Russell Nichols, Vladimir Skljarevski, Grazia Dell'Agnello, et al.
Headache
|
November 22, 2018
Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies
Russell Nichols, Erin Doty, Sara Sacco, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
September 15, 2020
Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN)
Janet Ford, Cristina Tassorelli, Elizabeth Leroux, et al.
Page
of 2